Document Detail

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.
MedLine Citation:
PMID:  23351925     Owner:  NLM     Status:  MEDLINE    
Many developments have occurred since the publication of the widely-used 2009 Canadian Cardiovascular Society (CCS) Dyslipidemia guidelines. Here, we present an updated version of the guidelines, incorporating new recommendations based on recent findings and harmonizing CCS guidelines with those from other Societies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used, per present standards of the CCS. The total cardiovascular disease Framingham Risk Score (FRS), modified for a family history of premature coronary disease, is recommended for risk assessment. Low-density lipoprotein cholesterol remains the primary target of therapy. However, non-high density lipoprotein cholesterol has been added to apolipoprotein B as an alternate target. There is an increased emphasis on treatment of higher risk patients, including those with chronic kidney disease and high risk hypertension. The primary panel has recommended a judicious use of secondary testing for subjects in whom the need for statin therapy is unclear. Expanded information on health behaviours is presented and is the backbone of risk reduction in all subjects. Finally, a systematic approach to statin intolerance is advocated to maximize appropriate use of lipid-lowering therapy. This document presents the recommendations and principal conclusions of this process. Along with associated Supplementary Material that can be accessed online, this document will be part of a program of knowledge translation. The goal is to increase the appropriate use of evidence-based cardiovascular disease event risk assessment in the management of dyslipidemia as a fundamental means of reducing global risk in the Canadian population.
Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Related Documents :
24161445 - Urinary phthalate metabolite concentrations among pregnant women in northern puerto ric...
23181645 - Differences in women's psychological well-being based on infertility treatment choice a...
23431075 - Associations between hemodialysis access type and clinical outcomes: a systematic review.
8374185 - Recurrence of sudden infant death syndrome among siblings.
25377535 - Socio-economic status and co-morbidity as risk factors for trauma.
24822065 - Vitamin d binding protein affects the correlation of 25(oh)d and frailty in the older men.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  29     ISSN:  1916-7075     ISO Abbreviation:  Can J Cardiol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  2013-03-26     Revised Date:  2014-03-10    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  151-67     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases* / diagnosis,  etiology,  prevention & control
Dyslipidemias* / complications,  diagnosis,  therapy
Hypolipidemic Agents / therapeutic use*
Practice Guidelines as Topic / standards*
Societies, Medical*
Reg. No./Substance:
0/Hypolipidemic Agents
Comment In:
Can J Cardiol. 2014 Feb;30(2):248.e3   [PMID:  23830292 ]
Can J Cardiol. 2014 Feb;30(2):248.e5   [PMID:  24095223 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cilia, Wnt signaling, and the cytoskeleton.
Next Document:  Canadian cardiovascular society guidelines on the use of cardiac resynchronization therapy: evidence...